In that very well-designed study, they tried to evaluate the relationships between levels of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein (MRP), and lung resistance-related protein (LRP) and median survival in patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and reactive lymphadenopathy (LAP). This evidence concerns the gene MVP and Hodgkins lymphoma.